Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CIT | O14578 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20508491 | 1.00 | UHRF1 (0.48) | UHRF1ROCK1PRCPADRB2DYRK1A | |
| Hydrochloric Acid SCHEMBL2749332 | 0.98 | UHRF1 (0.46) | UHRF1ROCK1PRCPADRB2DYRK1A | |
| SCHEMBL84469 | 0.82 | UHRF1 (0.52) | UHRF1PRCPDYRK1AHDAC4HDAC1 | |
| SCHEMBL30490644 | 0.82 | UHRF1 (0.52) | UHRF1PRCPDYRK1AHDAC4HDAC1 | |
| SCHEMBL20247131 | 0.81 | UHRF1 (0.46) | UHRF1PRCPDYRK1AKDM4EMEN1 | |
| SCHEMBL2610400 | 0.80 | UHRF1 (0.50) | UHRF1DYRK1ACITHDAC4HDAC1 | |
| SCHEMBL21762132 | 0.78 | UHRF1 (0.48) | UHRF1PRCPDYRK1AKDM4EMEN1 | |
| SCHEMBL4322612 | 0.78 | NOS3 (0.50) | ROCK1ADRB2DYRK1ACITKDM4E | |
| SCHEMBL17000190 | 0.78 | UHRF1 (0.48) | UHRF1PRCPDYRK1AKDM4EMEN1 | |
| SCHEMBL19846691 | 0.78 | UHRF1 (0.48) | UHRF1PRCPDYRK1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | claimed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
| US-20220119388-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-09-27 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | GENENTECH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8846945-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | DILLON MICHAEL PATRICK (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2592070-A2 | Tetrazole-substituted arylamides | F. Hoffmann-La Roche AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | DILLON MICHAEL PATRICK (US) | 2012-08-23 | — | — | US | disclosed |
| US-8193368-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| US-4797411-A | ANTITUMOR AGENTS | FARMITALIA CARLO ERBA S.P.A. (IT) | 1989-01-10 | — | — | US | disclosed |
| EP-0253681-A2 | Cycloalkyl-substituted 4-pyridyl derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | P2RX2, P2RX3, TPX2 | UHRF1 4528/4885ROCK1 3309/4885PRCP 1145/4885 |
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDH2, CYP4B1, RB1 | UHRF1 1901/4885ROCK1 2236/4885PRCP 1949/4885 |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | UHRF1 4314/4885ROCK1 4785/4885PRCP 1904/4885 |
| US-20220119388-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | UHRF1 2761/4885ROCK1 229/4885PRCP 2883/4885 |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | P2RX2, P2RX3, TPX2 | UHRF1 4489/4885ROCK1 3301/4885PRCP 1174/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | UHRF1 2509/4885ROCK1 159/4885PRCP 3603/4885 |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | UHRF1 2761/4885ROCK1 229/4885PRCP 2883/4885 |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | UHRF1 4314/4885ROCK1 4785/4885PRCP 1904/4885 |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | P2RX3, P2RX2, P2RX5 | UHRF1 4314/4885ROCK1 4785/4885PRCP 1904/4885 |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX5 | UHRF1 4314/4885ROCK1 4785/4885PRCP 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.